These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29463133)

  • 21. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.
    Andrade JM; Paraíso AF; de Oliveira MV; Martins AM; Neto JF; Guimarães AL; de Paula AM; Qureshi M; Santos SH
    Nutrition; 2014; 30(7-8):915-9. PubMed ID: 24985011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus.
    Fan Y; Xiong W; Li J; Hu A; He Z; Zhang J; Zhou G; Yin Q
    Pharm Biol; 2018 Dec; 56(1):567-572. PubMed ID: 30460863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
    Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
    Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
    Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
    Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Role of SIRT1/ FGF-21 in Taurine Protection Against Cafeteria Diet-Induced Steatohepatitis in Rats.
    Abd Elwahab AH; Ramadan BK; Schaalan MF; Tolba AM
    Cell Physiol Biochem; 2017; 43(2):644-659. PubMed ID: 28942443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of low-dose resveratrol attenuated hepatic inflammation and lipid accumulation in high cholesterol-fructose diet-induced rat model of nonalcoholic fatty liver disease.
    Chang CC; Chang CY; Lin PC; Huang JP; Chen KH; Yen TH; Hung LM
    Chin J Physiol; 2020; 63(4):149-155. PubMed ID: 32859881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does propolis have any effect on non-alcoholic fatty liver disease?
    Kismet K; Ozcan C; Kuru S; Gencay Celemli O; Celepli P; Senes M; Guclu T; Sorkun K; Hucumenoglu S; Besler T
    Biomed Pharmacother; 2017 Jun; 90():863-871. PubMed ID: 28437890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of resveratrol on intestinal oxidative status and inflammation in heat-stressed rats.
    Cheng K; Song Z; Li S; Yan E; Zhang H; Zhang L; Wang C; Wang T
    J Therm Biol; 2019 Oct; 85():102415. PubMed ID: 31657756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system.
    Tiao MM; Lin YJ; Yu HR; Sheen JM; Lin IC; Lai YJ; Tain YL; Huang LT; Tsai CC
    Lipids Health Dis; 2018 Jul; 17(1):178. PubMed ID: 30055626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antioxidative, anti-inflammatory and hepatoprotective effects of resveratrol on oxidative stress-induced liver damage in tilapia (Oreochromis niloticus).
    Jia R; Li Y; Cao L; Du J; Zheng T; Qian H; Gu Z; Jeney G; Xu P; Yin G
    Comp Biochem Physiol C Toxicol Pharmacol; 2019 Jan; 215():56-66. PubMed ID: 30336289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease.
    Poulsen MK; Nellemann B; Bibby BM; Stødkilde-Jørgensen H; Pedersen SB; Grønbaek H; Nielsen S
    Diabetes Obes Metab; 2018 Oct; 20(10):2504-2509. PubMed ID: 29885082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
    Zaitone SA; Barakat BM; Bilasy SE; Fawzy MS; Abdelaziz EZ; Farag NE
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):587-600. PubMed ID: 25708949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications.
    Karimi M; Abiri B; Guest PC; Vafa M
    Methods Mol Biol; 2022; 2343():19-35. PubMed ID: 34473313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
    Tipoe GL; Ho CT; Liong EC; Leung TM; Lau TY; Fung ML; Nanji AA
    Histol Histopathol; 2009 Sep; 24(9):1161-9. PubMed ID: 19609863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver.
    Kasdallah-Grissa A; Mornagui B; Aouani E; Hammami M; El May M; Gharbi N; Kamoun A; El-Fazaâ S
    Life Sci; 2007 Feb; 80(11):1033-9. PubMed ID: 17258234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Resveratrol Alleviates the Hepatic Toxicity of CuSO
    Tian Y; Wu B; Li X; Jin X; Zhang F; Jiang C; Xu W; Li H; Wang H
    Biol Trace Elem Res; 2019 Feb; 187(2):464-471. PubMed ID: 29980948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress.
    Gómez-Zorita S; Fernández-Quintela A; Macarulla MT; Aguirre L; Hijona E; Bujanda L; Milagro F; Martínez JA; Portillo MP
    Br J Nutr; 2012 Jan; 107(2):202-10. PubMed ID: 21733326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effects of Kangxian ruangan capsule against nonalcoholic fatty liver disease fibrosis in rats induced by MCD diet.
    Liu L; Zhou Y; Dai D; Xia H; Zhao K; Zhang J
    Biomed Pharmacother; 2018 Dec; 108():424-434. PubMed ID: 30236852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.